Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Other
  • ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
  • Other

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

BioPharma Dive

At the year s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Oncology

Read full story

pharminent June 2, 2026 (Last updated: June 4, 2026)

BioPharma Dive

At the year s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.

Oncology

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: ASCO26: Symptom-tracking app helps advanced cancer patients
Next: The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs

Related Stories

  • Other

ASCO26: Symptom-tracking app helps advanced cancer patients

pharminent June 2, 2026
  • Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026
  • Other

225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics Accelerator

pharminent May 18, 2026

You May Have Missed

  • Commercial

Lilly and Novo face off at ADA 2026 as others seek to compete in obesity

pharminent June 5, 2026
  • Market Access

Medicare Advantage in 2026: Enrollment Update and Key Trends

pharminent June 5, 2026
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

pharminent June 5, 2026
  • Clinical Data

Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data

pharminent June 5, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.